indazoles has been researched along with crizotinib in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Goozner, M | 1 |
| Carver, BS; Doran, MG; Evans, MJ; Sawyers, CL; Spratt, DE; Ulmert, D; Wongvipat, J | 1 |
| Affolter, T; Christensen, J; Eisele, K; Eswaraka, J; Feng, Z; Giddabasappa, A; Han, G; Lalwani, K; Li, G | 1 |
| Adelaiye, R; Barrera, G; Ciamporcero, E; Ku, S; Miles, KM; Pili, R; Pizzimenti, S; Ramakrishnan, S; Sennino, B; Shen, L | 1 |
| Ali, SM; Balasubramanian, S; Do, IG; Hong, JY; Hornby, Z; Huh, JW; Jang, J; Kang, WK; Kim, HC; Kim, KM; Kim, SH; Kim, ST; Kim, SY; Lee, J; Lee, WY; Li, GG; Lim, HY; Miller, VA; Ou, SH; Park, JO; Park, YA; Park, YS; Ross, JS; Stephens, PJ; Wang, K; Yun, SH | 1 |
| Abdollahi, A; Alves, F; Chiblak, S; Fuchs, B; Jannasch, K; Kleeff, J; Lindner, T; Matzke-Ogi, A; Mier, W; Morton, J; Orian-Rousseau, V; Ponta, H; Sansom, O; Schwager, C; Shatirishvili, M; Tawk, B; Warth, A | 1 |
| Arcila, M; Bauer, T; Berger, M; Cam, NR; Christiansen, J; Dogan, S; Drilon, A; Farago, A; Ghossein, R; Gounder, M; Hechtman, J; Ho, AL; Hornby, Z; Hyman, DM; Katabi, N; Ladanyi, M; Li, G; Lim, J; Liu, SV; Luo, D; Maneval, EC; Multani, P; Ou, SH; Patel, M; Shaw, A; Shen, R; Shoemaker, RF; Wang, L; Wei, G | 1 |
| Borgel, S; Bottaro, DP; Doroshow, JH; Evrard, YA; Hollingshead, MG; Ji, JJ; Khin, SA; Kinders, RJ; Linehan, WM; Navas, T; Parchment, RE; Pfister, TD; Srivastava, AK; Tomaszewski, JE; Weiner, J; Zhang, Y | 1 |
| Ali, SM; Amini, B; Elvin, JA; Erlich, RL; Gowen, K; Holmes, O; Meric-Bernstam, F; Miller, V; Piha-Paul, S; Ross, JS; Schrock, AB; Spritz, D; Stephens, PJ; Stockman, DL; Subbiah, V; Suh, JH; Vergilio, JA; Wang, WL; Zarzour, M; Zinner, R | 1 |
| Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M | 1 |
| Fujita, N; Gong, B; Hanzawa, H; Hata, AN; Isoyama, T; Iwasaki, S; Kagoshima, Y; Kamai, Y; Katayama, R; Kiga, M; Koike, S; Miyamoto, M; Nakao, N; Nishio, M; Oh-Hara, T; Seto, Y; Shaw, AT; Shimizu, Y; Takeda, Y; Togashi, N; Tominaga, Y; Watanabe, K; Yanagitani, N; Yoda, S | 1 |
| Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
| Brezinová, B; Chovanec, M; Dubovan, P; Gomolčáková, J; Jurišová, S; Mardiak, J; Mego, M; Rejlekova, K | 1 |
| Domoto, H; Hashiguchi, MH; Hiroshima, Y; Kagyo, J; Kato, T; Matsuzaki, T; Nakahara, Y; Sato, T; Shiomi, T; Watanabe, R; Yokose, T | 1 |
| Bartolome, L; Camidge, DR; Cappelleri, JC; Daniele, P; Groff, M; Iadeluca, L; Tremblay, G; Usari, T; Wilner, K; Wiltshire, R | 1 |
| Cappabianca, L; Farina, AR; Mackay, AR; Ruggieri, M; Sbaffone, M; Sebastiano, M; Zelli, V | 1 |
1 review(s) available for indazoles and crizotinib
| Article | Year |
|---|---|
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones | 2017 |
15 other study(ies) available for indazoles and crizotinib
| Article | Year |
|---|---|
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.
Topics: Anilides; Animals; Axitinib; Bone Regeneration; Crizotinib; Fluorine Radioisotopes; Fractures, Bone; Imidazoles; Indazoles; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Radiopharmaceuticals; Technetium Tc 99m Medronate; Tomography, Emission-Computed, Single-Photon | 2014 |
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bone Density; Bone Neoplasms; Cell Line, Tumor; Crizotinib; Humans; Imidazoles; Indazoles; Male; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Pyridines; Xenograft Model Antitumor Assays | 2014 |
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Crizotinib; Female; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genomics; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Male; Middle Aged; Mutation; Phosphorylation; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Tissue Array Analysis; Young Adult | 2015 |
Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Hyaluronan Receptors; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Peptides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Rats; RNA, Messenger; Signal Transduction; Sulfonamides; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2016 |
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Topics: Adult; Benzamides; Biomarkers, Tumor; Carcinoma, Acinar Cell; Clinical Trials as Topic; Crizotinib; Diagnosis, Differential; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Indazoles; Mammary Analogue Secretory Carcinoma; Mutation; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Salivary Gland Neoplasms | 2016 |
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Topics: A549 Cells; Animals; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Crizotinib; HEK293 Cells; HT29 Cells; Humans; Immunoassay; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Small Molecule Libraries; Stomach Neoplasms; Sulfonamides; Sulfones; Xenograft Model Antitumor Assays | 2016 |
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
Topics: Adolescent; Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Crizotinib; Female; Humans; Indazoles; Intestinal Neoplasms; Liver Neoplasms; Male; Middle Aged; Neuroectodermal Tumors; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Vascular Endothelial Growth Factor A; Young Adult | 2016 |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Topics: Aminopyridines; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Development; Drug Resistance, Neoplasm; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Membrane Glycoproteins; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor, trkB | 2019 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Targeted therapy in Xp11 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Crizotinib; Disease Progression; Everolimus; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Nivolumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Tomography, X-Ray Computed | 2021 |
A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Topics: Adenocarcinoma of Lung; Adult; Benzamides; Crizotinib; Female; Gene Rearrangement; Genomics; Humans; Indazoles; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2021 |
Effectiveness of crizotinib versus entrectinib in
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Treatment Outcome | 2022 |
Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells.
Topics: Alternative Splicing; Benzamides; Calmodulin; Cell Line, Tumor; Crizotinib; Doxorubicin; Humans; Indazoles; Neuroblastoma; Oxygen; Proto-Oncogene Proteins c-akt; Receptor, trkA; Ryanodine Receptor Calcium Release Channel | 2022 |